Avantium Technologies and Warwick Effect Polymers (WEP) have announced that they have reached agreement for the joint development and commercialization of WEP’s POLY PEG® technology for (bio) pharmaceutical compounds.
POLY PEG® is a drug-delivery solution to enhance the development of therapeutic products such as peptides, monoclonal antibodies and recombinant proteins.
POLY PEG® technology has been developed to increase the bioavailability of drug molecules.
By improving the bioavailability of drug molecules and optimizing their pharmacokinetic profile, patients can benefit by decreased dosing frequencies and increased drug efficacy.
"We are very pleased to enter this agreement with Avantium," said WEP’s CTO, Professor David Haddleton.
"Avantium is a leading company in high-throughput experimentation. Their experience in PEGylation process improvement and network of contacts throughout the industry will allow us to speed the development process, while enhancing the licensing opportunities for our POLY PEG® technology."
"We welcome this opportunity to collaborate with Warwick Effect Polymers," said Tom van Aken, CEO of Avantium.
"We see great potential in WEP’s POLY PEG® technology, because it can improve and prolong the performance of drug molecules."
"We believe that our partners and future customers can benefit significantly from the collaboration between WEP and Avantium to commercialize POLY PEG® technology."